Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q945537> ?p ?o }
Showing triples 1 to 54 of
54
with 100 triples per page.
- Q945537 subject Q5856563.
- Q945537 subject Q6946436.
- Q945537 subject Q8761830.
- Q945537 subject Q8965786.
- Q945537 abstract "Tofisopam (Emandaxin, Grandaxin, Sériel) is an anxiolytic that is marketed in several European countries. Chemically, it is a 2,3-benzodiazepine. Unlike other anxiolytic benzodiazepines (which are generally 1,4- or 1,5-substituted) however, tofisopam does not have anticonvulsant, sedative, skeletal muscle relaxant, motor skill-impairing or amnestic properties. While it may not be an anticonvulsant in and of itself, it has been shown to enhance the anticonvulsant action of classical 1,4-benzodiazepines such as diazepam (but not sodium valproate, carbamazepine, phenobarbital, or phenytoin). Tofisopam is indicated for the treatment of anxiety and alcohol withdrawal, and is prescribed in a dosage of 50–300 mg per day divided into three doses. Peak plasma levels are attained two hours after an oral dose. Tofisopam is not reported as causing dependence to the same extent as other benzodiazepines, but is still recommended to be prescribed for a maximum of 12 weeks.Tofisopam is not approved for sale in the United States or Canada. However, Vela Pharmaceuticals of New Jersey is developing the D-enantiomer (dextofisopam) as a treatment for irritable bowel syndrome, with moderate efficacy demonstrated in clinical trials so far.Tofisopam is also claimed to be a PDE10A inhibitor, which may provide an alternative mechanism of action for its various therapeutic effects, and this action has been proposed to make tofisopam potentially useful as a treatment for schizophrenia.Tofisopam has been shown to act as an inhibitor of the liver enzyme CYP3A4, and this could potentially cause dangerous drug interactions with other medications metabolised by this enzyme, although the clinical significance of these findings remains unclear.".
- Q945537 atcPrefix "N05".
- Q945537 atcSuffix "BA23".
- Q945537 casNumber "22345-47-7".
- Q945537 drugbank "DB08811".
- Q945537 fdaUniiCode "UZC80HAU42".
- Q945537 iupacName "1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine".
- Q945537 pubchem "5502".
- Q945537 thumbnail Tofisopam_structure.svg?width=300.
- Q945537 wikiPageExternalLink pim686.htm.
- Q945537 wikiPageWikiLink Q11072.
- Q945537 wikiPageWikiLink Q1225289.
- Q945537 wikiPageWikiLink Q13208902.
- Q945537 wikiPageWikiLink Q14864419.
- Q945537 wikiPageWikiLink Q154430.
- Q945537 wikiPageWikiLink Q240642.
- Q945537 wikiPageWikiLink Q2914873.
- Q945537 wikiPageWikiLink Q407241.
- Q945537 wikiPageWikiLink Q410400.
- Q945537 wikiPageWikiLink Q410412.
- Q945537 wikiPageWikiLink Q41112.
- Q945537 wikiPageWikiLink Q418251.
- Q945537 wikiPageWikiLink Q46.
- Q945537 wikiPageWikiLink Q494483.
- Q945537 wikiPageWikiLink Q576618.
- Q945537 wikiPageWikiLink Q5856563.
- Q945537 wikiPageWikiLink Q62903.
- Q945537 wikiPageWikiLink Q6946436.
- Q945537 wikiPageWikiLink Q83871.
- Q945537 wikiPageWikiLink Q838966.
- Q945537 wikiPageWikiLink Q847705.
- Q945537 wikiPageWikiLink Q8761830.
- Q945537 wikiPageWikiLink Q8965786.
- Q945537 wikiPageWikiLink Q9368.
- Q945537 wikiPageWikiLink Q9377.
- Q945537 atcPrefix "N05".
- Q945537 atcSuffix "BA23".
- Q945537 casNumber "22345".
- Q945537 drugbank "DB08811".
- Q945537 iupacName "1".
- Q945537 pubchem "5502".
- Q945537 unii "UZC80HAU42".
- Q945537 type ChemicalSubstance.
- Q945537 type Drug.
- Q945537 type ChemicalObject.
- Q945537 type Thing.
- Q945537 type Q8386.
- Q945537 comment "Tofisopam (Emandaxin, Grandaxin, Sériel) is an anxiolytic that is marketed in several European countries. Chemically, it is a 2,3-benzodiazepine. Unlike other anxiolytic benzodiazepines (which are generally 1,4- or 1,5-substituted) however, tofisopam does not have anticonvulsant, sedative, skeletal muscle relaxant, motor skill-impairing or amnestic properties.".
- Q945537 label "Tofisopam".
- Q945537 depiction Tofisopam_structure.svg.
